Clinical Trial

A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The primary objective of this study is to determine the efficacy and safety profiles of 2 doses and 2 dosing regimens of EYP001a versus placebo on liver fat content (LFC) from baseline to Week 12 in patients with NASH.


Principal Investigator Marcel Twahirwa, MD
Type of Trial Prospective/Interventional